After a period of diversification, Novo Nordisk is returning to its roots by focusing on the 2 billion people with diabetes, ...

Novo Nordisk CEO Mike Doustdar said on Tuesday the drugmaker expects headwinds in its international operations in 2026, as ...

Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of ...

The past year was one of turbulence and change at Novo Nordisk, and, while the Danish drugmaker still has its work cut out ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

SAN FRANCISCO, Jan 12 (Reuters) - Oral weight-loss drugs could account for a third or more of the overall GLP-1 market by ...

Novo Nordisk ( NVO +1.68%) was once the top player in the weight loss drug market. The company's medicine, Wegovy, ...

Novo Nordisk A/S (NOVO:CA) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 12:45 PM ESTCompany ...

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable ...

Eli Lilly won approval for its tirzepatide under the names Mounjaro for type 2 diabetes and Zepbound for weight loss -- in ...

Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...